Recommendation of the President – Mektovi (binimetinib)

On 4 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 13/2026 on the reimbursement of the medicinal product Mektovi (binimetinib) under the B.6. drug program. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)”

Publication in Public Information Bulletin (BIP) >>